Company Overview of NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of therapeutics for the treatment of cardio-metabolic diseases, liver diseases, and cancer. It offers NGM282, a protein variant of FGF19 for the treatment of bile acid related diseases (BARD) and non-alcoholic steatohepatitis (NASH); NGM386 and NGM395, protein variants of NP201 developed for the treatment of metabolic conditions, such as type 2 diabetes, obesity, and NASH; and NGM313, an agonistic antibody of the beta-klotho (KLB)/FGFR1c pathway. NGM Biopharmaceuticals, Inc. has strategic partnerships with Merck, MedImmune, and JDRF. The company was incorporated in 2007 and is based in S...
630 Gateway Boulevard
South San Francisco, CA 94080-7014
Founded in 2007
Key Executives for NGM Biopharmaceuticals, Inc.
Chief Executive Officer and Director
Founder, Chief Scientific Officer and Director
Chief Operating Officer and Vice President
Compensation as of Fiscal Year 2016.
NGM Biopharmaceuticals, Inc. Key Developments
NGM Biopharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2016, Aug-16-2016 01:55 PM
Aug 9 16
NGM Biopharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2016, Aug-16-2016 01:55 PM. Venue: Le Parker Meridien, New York, New York, United States.
NGM Biopharmaceuticals, Inc. Presents at 36th Annual Canaccord Genuity Growth Conference 2016, Aug-10-2016 03:00 PM
Aug 7 16
NGM Biopharmaceuticals, Inc. Presents at 36th Annual Canaccord Genuity Growth Conference 2016, Aug-10-2016 03:00 PM. Venue: InterContinental Hotel, Boston, Massachusetts, United States.
NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and Nash
Jun 8 16
NGM Bio reported initiation of a Phase 1 trial of NGM313 in overweight or obese volunteers. NGM313 is an agonistic antibody engineered to selectively activate the beta-klotho (KLB)-FGFR1c receptor complex and promote beneficial metabolic activity. NGM313 was discovered and is being developed by NGM Bio as a potential treatment for type 2 diabetes, obesity and nonalcoholic steatohepatitis (NASH). Under the terms of a collaboration agreement with Merck Sharp and Dohme Corp. ("Merck") executed in 2015, Merck has an exclusive, one-time option to license NGM313 following completion of a human proof of concept study. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled trial to investigate the safety, tolerability and pharmacokinetic profile of NGM313 after single and multiple ascending doses. The study will also measure a variety of biomarkers associated with metabolic regulation. Data from the trial are expected in 2017.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|